New prostate cancer treatment plus local therapy for metastatic cases
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and have prostate cancer confirmed on pathology (biopsy/surgery tissue).
- Have metastatic disease shown on a bone scan (at least one bone spot); if only one bone spot, it must be confirmed by CT or MRI.
- Have good day-to-day functioning (ECOG performance status 0–2).
- Have not had prior hormone-blocking medicines like antiandrogens or GnRH shots (or you had them no more than 3 months ago).
- Have adequate blood and organ tests (enough white blood cells, hemoglobin, platelets; kidney function; and acceptable liver function).
- Be able to swallow apalutamide tablets whole and be willing to sign consent and follow study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial is testing whether giving prostate removal surgery in addition to standard hormone therapy can help men with advanced prostate cancer that has spread to many places. It aims to see if this combination helps them live longer with a better quality of life.
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.